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THE USE OF PROTEOLYTIC ENZYMES (CHYMORAL) IN SPORTING INJURIES*
W. F. (ROB) RATHGEBER, M.B., B.CH. (RAND), DI/rban
TABLE t. SITES OF INJURIES
On entry into the trial full details of the nature and
site of injury were entered on the patient's record card,
together with emergency treatment given. Each record
card was given a consecutive code number which corre-
sponded with a container of tablets, and the patient was
instructed to take 2 tablets 4 times a day, half an hour
before meals. The tablets were either Chymoral or a
MATERlALS AND METHODS
The patients incorporated in the trial were those suffering
from sporting injuries. These were sustained in various
types of activities, including football, rugby, tennis, cricket,
squash racquets and athletics. The types of injuries were
soft-tissue damage to virtually every part of the body,
including the hands, feet, head, chest, knees and ankles,
as indicated in Table I. In some cases stitching and
pressure strapping were required, and in all cases routine
emergency treatment was employed.
It is also important from the players' point of view,
particularly if they are professionals, as not only do they
suffer pain and discomfort associated with accidental
trauma, but they may also suffer financial loss in their
inability to participate.
Th~ resolution of inflammatory oedema, bruising and
swelling is difficult to assess objectively. Over a period
of years familiarity with the normal recovery processes
can be estimated objectively if the doctor concerned
regularly attends to these types of injuries. This is parti-
cularly so if patients are suffering from trauma associated
with areas of the body that cannot easily be measured,
such as the head and chest.
It was therefore decided to complete work on a varied
selection of cases suffering from soft-tissue damage as a
result of sporting injuries, using either Chymoral or place-
bo in a double-blind trial. The patients were often seen
at the sporting events where they sustained the injury
and the doctor was responsible for supervising the require-
ments of personnel in the field, or occasionally in casualty
departments of local hospitals. The object of the trial
was to return the patient to play as quickly as possible
by the resolution of traumatic oedema which woul!!



































le received: 12 October 1970.
exact mode of action of proteolytic enzymes in the
iution of accidental or postoperative oedema is not
Nn. Many workers have suggested that these drugs
k down fibrous material, blocking the Iymphatics and
lIaries, ibereby restoring microcirculation. The theory,
ever, still remains to be proved as are also the exact
; leading to the build-up of inflammatory oedema.
rlzymes are important complex compounds which have
pharmacological effects both in the general processes
ioestion and at tissue level. Ambrus et a'.' have shown
";;hymotrypsin and trypsin can be absorbed across
abdominal wall. This itself appeared to be a factor
was initially queried by many members of the medical
scientific professions. They went on to say that the
that proteolytic enzymes could not be absorbed
tUse of their molecular size could be discounted as
ecules of 10 times their size could be shown to be
>rbed. Ambrus et al. showed that when enzymes were
:n with food a considerable amount of their activity
lost in the normal digestive processes. It is therefore
ntial that the proteolytic enzymes should be taken
n the stomach is empty, preferably t - 1 hour before
Is.
ie et al.' were able to use objective parameters in
ssing the value of the proteolytic enzymes in post-
rative trauma of the hand. The circumferential
.surements of the fingers and palms were taken pre-
postoperatively and a comparison was made between
ents using either Chymoral or a placebo. The results
lined showed a statistically significant improvement
he patients taking the active drug, reducing the time
:esolution of inflammatory oedema by 50%.
10nstein3 was able to show considerable improvement
boxers who used proteolytic enzymes both prophy-
icaUy and therapeutically. In this trial the double-blind
mique was used and the patients taking the active drug
wed an excellent response in respect of the time of
wery. Similar results were obtained by Boyne and
dhurst' when using proteolytic enzymes in accidental
lma associated with footballers and comparing the
}lts of two seasons' injuries. Shaw' and Lie et al.' have
lerlined the importance of reducing inflammatory
ema. They state that this often becomes fibrinous and
y eventually reduce the mobility of the limb or termi-
extremity. Pain and discomfort are prolonged and
Imatic oedema often indirectly gives rise to scarring.
'he essential point to bear in mind in relating the
IltS of these trials to trauma associated with sporting
lries, is that if key personnel are away from their
m for considerable periods of time their morale is
uced and their fitness is lost due to long periods away
m participation in games or training. It is also difficult
encourage continued fitness despite rehabilitation pro-
mmes, if a player is injured. If, therefore, time lost
: to accidental trauma can be reduced and the players
llrned to full function, considerable economies can be
:cted in the general running of sporting organizations.
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placebo prepared in identical form and packed in identical
containers so that neither the doctor nor the patient knew
which treatment was being received. The treatment was
continued for 5 days. The patient was seen every day or
every other day where possible so that an accurate assess-
ment of his progress could be made.
The parameters used in assessing progress were: bruising
and swelling---classified as nil, minimal, moderate and
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When the code was broken it was found that 26 patients
received the active drug while 20 patients received the
placebo drug. Three patients receiving the active drug
were excluded from the trial for various reasons-thus
leaving only 23 patients receiving the active drug for
analysis.
The age range of the patients in the trial was compara-
ble, viz.: patients receiving Chymoral were aged 6 - 36
years (average 22 years) and patients receiving the placebo
were aged 9 - 40 years (average 26t years).
It was found that in the parameters bruising, swelling
and return to full function, there were exclusions. These
are noted in the results column as the patients did not
register any degree of either bruising or swelling, and in
return to full function this did not apply as 3 of the
patients receiving Chymoral sustained head injuries, and
1 patient receiving the placebo was incapacitated with a
bruised penis as a result of a kick in the groin. The
results were compared on the sixth day as this was the
day when all the patients had completed the course of
treatment and no further therapeutic effect could be
anticipated. In the estimate of return to full function it
was decided to record the patients who had more than
80% of full function as a fair assessment of recovery
(Table II).
DISCUSSION
Statistically significant results were obtained in 3 of the
4 parameters: bruising, return to function, and fitness to
TABLE n. PROGRESS OF TIlE PATIENTS
Days
Over %
Excl. 1 2 3 4 5 6 7 8 9 10 11 12 recovery
on 6th day p value
Bruising-resolution in days
Patients receiving Chymoral 3 3 3 2 4 50 Significant
No bruising 5 P<0'02
Patients receiving placebo 2 8 12·5
No bruising 4
Swelling-resolution in days
Patients receiving Chymoral 2 4 3 3 3 53 Not
No swelling 4 significant
Patients receiving placebo 2 8 29 P<0'16
No swelling 6
Return to full function-in days
(minimum 80%)
Patients receiving ChymoraI 1 2 6 3 2 2 2 65 Significant
EXcluding head injuries 3 P<O'OI
Patients receiving placebo 2 2 3 2 8 16
Excluding bruised. penis
Fit to play-in days
Patients receiving Chymoral 3 3 5 3 3 1 70 Significant
Patients receiving placebo 4 1 12 20 P<O'Ol
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E Ill. NUMBER OF CASES FIT TO PLAY AND % FIT TO PLAY
ON DAYS TIlROUGHOUT TRIAL
S receiving Chymoral Ca~es receiving placebo
% %
No. fit to fit to No. fit to fit to
play play Day play play
3 13 1 4 20
4 18 6 5 25
7 30 7 6 30
8 35 8 7 35
13 57 9 8 40
16 70 10 10 50
18 79 11 11 55
20 88 14 12 60
21 92 15 13 65
22 96 16 15 75




" and in each case the probability was less than 0·02.
lOUgh there was a considerable reduction in swelling
the sixth day in 53-% of the patients receiving the
ve drug as compared with 29% of the patients re-
ing the placebo on the same day, this was not statis-
lIy significant (Table II).
hroughout the trial it is interesting to note the number
cases that were either resolved or recovered before
12th day in the patients receiving Chymoral as com-
~d with those receiving the placebo. It is normally
cipated in these types of injuries, serious enough to
i medical attention, that the approximate time of re-
ery, and therefore fitness to play, can be as long as
21 days. In the trial, and with the use of Chymoral,
period was considerably reduced. Accumulated cases
in the various parameters showed that only 8 cases had
not been resolved in 12 days, using Chymoral, whereas
there were 36 recordings of cases using the placebo.
Table III and Fig. I show the number of patients and
the percentage of patients who had recovered sufficiently
to play, on the days throughout the trial, and clearly
illustrate the difference in effectiveness of the two drugs,
Chymoral and placebo. The average time for recovery of
patients receiving Chymoral was 8t days and for patients
receiving placebo 17 days.
SUMMARY
A double-blind trial with either Chymoral or a placebo, on
patients sustaining injuries due to accidental trauma in sport.
was completed on 43 cases.
Statistically significant results were achieved in 3 of the 4
parameters used, namely bruising, return to function, and
fitness to resume play. Although there was a considerable
reduction in the resolution of swelling in patients taking
Chymoral as compared with the placebo, this result was not
statistically significant. The assessment of the resolution of
inflammatory oedema in large limbs, chest and head is some-
times difficult, and this is probably the reason why a significant
result was not achieved in this parameter. The speed of the
recovery of patients treated with Chymoral is extremely valuable
in maintaining the important morale, personal fimess and skill
of the individual players.
It must be remembered that the patients treated were those
who were fit and active, where the normal recovery rate is
expected to be good. If it is possible, therefore, to improve the
normal recovery rate this is not only economically valuable,
but worthy of note from the clinical point of view.
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PASSING EVENTS: IN DIE VERBYGAAN
Basil de Saxe, surgeon, has resumed practice in Johannes-
g, having returned from a visit overseas where he visited
Breast Clinic and Plastic Surgery Unit at Guy's Hospital,
I the Breast Clinic at the Royal Postgraduate Medical
1001 at Hammersmith Hospital, London.
,thern Africa Cardiac Society, Johannesburg Branch. A
me will be given on Thursday 25 February at 8.15 p.m.
:he Pneumoconiosis Lecture Theatre, Joubert Street, Johan-
burg. The guest speaker will be Prof. A. J. Brink of
llenbosch University.
versity of fhe WitlVatersrand Medical Graduates Associa-
, PostgraduaTe Course in DermaTOlogy. A course in clini-
dermatology will be held by the Depart:nent of Dermato-
, from Thursday I April to Saturday 3 April 1971.
he course is designed for those in general practice. Empha-
will be laid on modern advances in the diagnosis and
tment of common skin disorders, skin manifestations of
mal disease, and demonstrations of diagnostic and thera-
tic procedures.
'he closing date is 22 February 1971 and the fee for the
rse is R25.oo (R20.oo for members of the Medical Graduates
ociation). The course programme will be submitted on
,Iication. Applications should be sent to the Secretary,







of the American College of Cardiology where he will repre-
sent the Southern Africa Cardiac Society. He will also visit
the Cleveland Clinic to study aspects of surgery for coronary
artery disease.
DepartmeJ1/ of Obstetrics and Gynaecology, Addington Hos-
piTal, Durban: G. P. Forum. A forum for general practitioners.
organized by the D~partment of Obstetrics and Gynaecology,
Addington Hospital, will be held on Wednesday 17 February
at 7.15 p.m. at the Marine Hotel. Esplanade, Durban. Drs R.
Wilson and M. S. Patterson will speak on 'The role of the G.P.
in problems related to sex'.
The forum which is being sponsored by Organon, will be
followed by a buffet supp~r. For the benefit of accompanying
doctors' wives, Dr J. Schneider will present a talk and de-
monstration on 'Antique silver'.
All general practitioners, gynaecologists and physicians are
invited to attend. Further details are available from Dr M.
Notelovitz, Dept of Obstetrics and Gynaecology, Addingron
Hospital, P.O. Box 977, Durban (telephone 2-6666).
"Sowh African InSTifllte for Medical Research, Johannesburg.
Staff Sciellfific Meetings. The next meeting will be held on
.Monday 22 February at 5.10 p.m. in the Auditorium, North
Block, SAIMR. Dr 1. J. Theron, Vice-President of the MRC,
will speak on 'The South African Medical Research Council'.
All interested persons will be welcome.
Monty M. Zion, physician, of Johannesburg, is at present
ting the USA. He will be attending the scientific session
University of Cape TOlVn and GroOTe Se/Will' Hospital, DeparT-
/IIent of Dermatology, Clinical Lectllres. The next meeting will
